Descartes 15
Alternative Names: Anti-BCMA mRNA CAR-T cell therapy - Cartesian Therapeutics; Anti-BCMA mRNA chimeric antigen receptor T cell therapy - Cartesian Therapeutics; Descartes-015; Descartes-15Latest Information Update: 28 Apr 2025
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
- No development reported Autoimmune disorders; Solid tumours
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 13 Jan 2025 Cartesian Therapeutics plans a clinical trial in Autoimmune disorders